--Analyst Actions: BTIG Research Initiates Coverage on Fate Therapeutics at Buy, PT $27
11:50AM ET 8/09/2019 MT NewswiresPrice: 18.44, Change: -0.81, Percent Change: -4.21 ...
Quotes Snapshot > FATE
Fate Therapeutics Inc FATE:NASDAQ
Last Price$18.74Cboe Real-Time Last Sale as of 10:20AM ET 8/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.25(1.32%)
Bid (Size)$18.70 (200)
Ask (Size)$18.81 (200)
Day Low / High$18.69 - 19.02
Volume29.9 K
Read more news Recent News
--Analyst Actions: Wedbush Raises Price Target on Fate Therapeutics to $26 From $21, Maintains Outperform
8:09AM ET 8/07/2019 MT NewswiresPrice: 19.82, Change: +0.55, Percent Change: +2.85 ...
Significant Insider Selling Continues at Fate Therapeutics (FATE)
10:17PM ET 8/05/2019 MT NewswiresThere was a notable sale of shares of Fate Therapeutics by an insider today, as revealed in a form 4 document filed with the SEC. One insider -- Dr Amir...
Insider Trends: Fate Therapeutics Insider Extends 90-Day Selling Trend
4:34PM ET 8/02/2019 MT NewswiresOn Jul 31, 2019, Director, Dr Amir Nashat, executed a sale of 62,005 shares in Fate Therapeutics (FATE) for $1,397,066. Dr Nashat, after the transactions...
View all Commentary and Analysis
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2019 Results - Earnings Call Transcript
11:59PM ET 8/06/2019 Seeking AlphaFate Therapeutics: Updates To Thesis, Gaining Momentum In The Clinic
9:41AM ET 7/18/2019 Seeking AlphaFate Therapeutics, Inc.'s (FATE) CEO Scott Wolchko on Q1 2019 Results - Earnings Call Transcript
11:37PM ET 5/07/2019 Seeking AlphaFate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2018 Results - Earnings Call Transcript
10:58PM ET 3/05/2019 Seeking AlphaCompany Profile
Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
| Address | 3535 General Atomics Court San Diego, California 92121 |
| Phone | +1.858.875.1800 |
| Number of Employees | 104 |
| Recent SEC Filing | 08/07/2019 8-K/A |
| President, Chief Executive Officer & Director | J. Scott Wolchko |
| Chief Scientific Officer | Daniel D. Shoemaker |
| Vice President-Clinical Development | Yu Waye Chu |
| Senior Vice President-Corporate Development | Jim Beitel |
Company Highlights
| Price Open | $18.81 |
| Previous Close | $18.99 |
| 52 Week Range | $10.78 - 22.82 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 65.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/07/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.22 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.7 M |
| Net Profit Margin | -934.70% |
| Return on Equity | -50.05% |
Analyst Ratings as of 08/08/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |